HYDROCHLOROTHIAZIDE - hydrochlorothiazide tablet

International Labs, Inc.

DESCRIPTION DESCRIPTION

Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide and it has the following structural formula:Enter section text here

$$H_2NSO_2$$
 NH
 $C_7H_8CIN_3O_4S_2$
 $M.W. 297.74$

Hydrochlorothiazide is a white, or practically white, crystalline powder which is slightly soluble in water, but freely soluble in sodium hydroxide

solution. Each tablet for oral administration contains 25 mg or 50 mg hydrochlorothiazide. In addition, each tablet contains the following

inactive ingredients: dibasic calcium phosphate, lactose monohydrate, pregelatinized starch, FDC yellow No. 6 lake, corn starch, colloidal

silicon dioxide, and magnesium stearate.

CLINICAL PHARMACOLOGY CLINICAL PHARMACOLOGY

The mechanism of the antihypertensive effect of thiazides is unknown. Hydrochlorothiazide does not usually affect normal blood pressure.

Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are

approximately equal in their diuretic efficacy.

Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by

some loss of potassium and bicarbonate.

After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.

Pharmacokinetics and Metabolism

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours,

the plasma half-life has been observed to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is eliminated unchanged within

24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

INDICATIONS AND USAGE INDICATIONS AND USAGE

Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and

corticosteroid and estrogen therapy.

Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute

glomerulonephritis, and chronic renal failure.

Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Use in Pregnancy

Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not

prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides

are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see

PRECAUTIONS,

Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus is properly treated through

elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and

unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular

disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will

often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic

therapy may provide relief and be appropriate.

CONTRAINDICATIONS CONTRAINDICATIONS

Anurio

Hypersensitivity to this product or to other sulfonamide-derived drugs.

WARNINGS

WARNINGS

Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug

may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid

and electrolyte balance may precipitate hepatic coma.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Lithium generally should not be given with diuretics (see PRECAUTIONS, Drug Interactions).

PRECAUTIONS

PRECAUTIONS

General

All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic

alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively

or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth,

thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria,

tachycardia, and gastrointestinal disturbances such as nausea and vomiting. Hypokalemia may develop, especially with brisk diuresis, when

severe cirrhosis is present, or after prolonged therapy.

Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmia and may

also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability).

Hypokalemia may

be avoided or treated by potassium sparing diuretics or potassium supplements such as foods with a high potassium content.

Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as

in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis. Dilutional hyponatremia may

occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances

when the hyponatremia is life threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazide.

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide

diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy.

The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient.

If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy.

Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia.

Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence

of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be

discontinued before carrying out tests for parathyroid function.

Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy.

Laboratory Tests

Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be done at appropriate intervals.

Drug Interactions

When given concurrently the following drugs may interact with thiazide diuretics.

Alcohol, barbiturates, or narcotics

Potentiation of orthostatic hypotension may occur.

Antidiabetic drugs - (oral agents and insulin)

Dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs

Additive effect or potentiation.

Cholestyramine and colestipol resins

Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol

resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.

Corticosteroids, ACTH

Intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., norepinephrine)

Possible decreased response to pressor amines but not sufficient to preclude their use.

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)

Possible increased responsiveness to the muscle relaxant.

Lithium

Generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer

to the package insert for lithium preparations before use of such preparations with hydrochlorothiazide.

Non-steroidal Anti-inflammatory Drugs

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive

effects of loop, potassium-sparing and thiazide diuretics. Therefore, when hydrochlorothiazide and non-steroidal anti-inflammatory agents

are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

Drug/Laboratory Test Interactions

Thiazides should be discontinued before carrying out tests for parathyroid function (see PRECAUTIONS, General).

Carcinogenesis, Mutagenesis, Impairment of Fertility

Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of

a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at

doses of approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepato-carcinogenicity in male mice. Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of Salmonella typhimurium strains TA 98, TA100, TA 1535, TA

1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell

chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results

were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse Lymphoma Cell (mutagenicity) assays,

using concentrations of hydrochlorothiazide from 43 to 1300 mcg/mL, and in the Aspergillus nidulans non-disjunction assay at an unspecified

concentration.

Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via

their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.

Pregnancy

Teratogenic Effects – Pregnancy Category B

Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis

at doses up to 3000 and 1000 mg hydrochlorothiazide/kg, respectively, provided no evidence of harm to the fetus.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nonteratogenic Effects

Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly

other adverse reactions that have occurred in adults.

Nursing Mothers

Thiazides are excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made

whether to discontinue nursing or to discontinue hydrochlorothiazide, taking into account the importance of the drug to the mother.

Pediatric Use

There are no well-controlled clinical trials in pediatric patients. Information on dosing in this age group is supported by evidence from empiric use in pediatric patients and published literature regarding the treatment of hypertension in such patients. (See **DOSAGE AND**

ADMINISTRATION, Infants and Children).

ADVERSE REACTIONS

ADVERSE REACTIONS

The following adverse reactions have been reported and, within each category, are listed in the order of decreasing severity.

Body as a whole

Weakness

Cardiovascular

Hypotension including orthostatic Hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs)

Digestive

Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea,

anorexia

Hematologic

Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia

Hypersensitivity

Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary

edema, photosensitivity, fever, urticaria, rash, purpura

Metabolic

Electrolyte imbalance (see PRECAUTIONS), hyperglycemia, glycosuria, hyperuricemia

Musculoskeletal

Muscle spasm

Nervous System/Psychiatric

Vertigo, paresthesias, dizziness, headache, restlessness

Renal

Renal failure, renal dysfunction, interstitial nephritis (see WARNINGS)

Skin

Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia

Special Senses

Transient blurred vision, xanthopsia

Urogenital

Impotence

Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.

OVERDOSAGE

OVERDOSAGE

The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia)

and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.

In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed.

Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial

respiration for respiratory impairment. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

HOW SUPPLIED

HOW SUPPLIED

Hydrochlorothiazide Tablets USP, 25 mg are light pink colored, round shaped, flat faced beveled edge uncoated tablets, debossed with 'D'

and '27' on one side separated by scoring and plain on the other side.

Shellpaks® of 30 tablets NDC 54458-939-10

PHARMACIST: Dispense in a well-closed container as defined in the USP. Use child-resistant closure (as required).

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Manufactured by:

Aurobindo Pharma Limited

Hyderabad-500 072, India

Packaged by:

International Labs, Inc.

St. Petersburg, FL 33710

Distributed by:

Wal-Mart

Bentonville, AR 72716

Rev. 12/09 LI0023

DOSAGE AND ADMINISTRATION DOSAGE AND ADMINISTRATION

Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.

Adults

For Edema

The usual adult dosage is 25 to 100 mg daily as a single or divided dose. Many patients with edema respond to intermittent therapy, i.e.,

administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting

undesirable electrolyte imbalance are less likely to occur.

For Control of Hypertension

The usual initial dose in adults is 25 mg daily given as a single dose. The dose may be increased to 50 mg daily, given as a single or two divided

doses. Doses above 50 mg are often associated with marked reductions in serum potassium (see also **PRECAUTIONS**).

Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily when used concomitantly with other antihypertensive

agents.

Infants and Children

For Diuresis and For Control of Hypertension

The usual pediatric dosage is 0.5 to 1 mg per pound (1 to 2 mg/kg) per day in single or two divided doses, not to exceed 37.5 mg per day in

infants up to 2 years of age or 100 mg per day in children 2 to 12 years of age. In infants less than 6 months of age, doses up to 1.5 mg per

pound (3 mg/kg) per day in two divided doses may be required. (See PRECAUTIONS, Pediatric Use).

HYDROCHLOROTHIAZIDE TABLETS, USP 25 MG - LABEL

LB0143 - HYDROCHLOROTHIAZIDE TABLETS, USP 25 mg



HYDROCHLOROTHIAZIDE TABLETS, USP 25 MG - INSERT

LI0023 - HYDROCHLOROTHIAZIDE TABLETS, USP 25 mg - PATIENT PACKAGE INSERT

Hydrochlorothiazide Tablets, USP Rx only

DESCRIPTION

Hydrochicothicatile is a distrate and antihypartensive. It is the 3.4-divylon derivative of chirothicatile. It is chemically designated as 6-chirot-5.4-ditysto-39-1,2,4-benochicatile-29-unitariantile (1,1-tiocids and it has the following structural formula:

Hydrochlocations to a white, or practically white, or prisiting powder which is slightly soluble in water, but havely estable in softem hydrocide solution. Each table for one inability indication contains the following inability in actition, each failest contains the following inability inability, each failest contains the following inability inability inability, and failing inability inability in actition, and failing inability inability in a fail or segment of the following inability in the fail of the fail or following in the fail in actition of the fail or failing in the fail in actition of the failing in the fail in actition of the fail or failing in the fail in actition of the failing in the fail in

The machinism of the entitlepertonoise officit of this piece is unknown. Hedrochicophic politication does not usually affect normal blood pressure. He describe of the affects the cloted sense to be described in the contract of sectoral to sense be described. At maximal there produces are approximately equal in their discribed effects,

Hydrochicostilisable increases except by of sedium and chloride in approximately equivalent amounts. Notituresis may be eccompanied by some loss of potassium and bleathereds.

After oral use diseasts begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.

Hy thrushicostilication in not metabolized but it all miscaled regists by the lettines. When placens levels have been followed that all beast 24 hours, it for placens level in the above in bearwards way between 5.5 but 1.4 ft hours, it level it presents if the virtual is called a rechanged within 24 hours, it is controlled to recover the placens that it is not that beloed on the senter and the vertical in beast milk.

INDICATIONS AND USAGE

Hydrochlorothiczilla tableta are indicated an adjunctive therapy in edoma associated with congestive heart failure, hapatic cirritosis, and cirritoralisated and witnings therapy.

Hy throshbrothis side tablets have also been found useful in edems due to various forms of renal dysfunction such as neg brotle syndroms, souls often white such as neg brotle syndroms, souls of the such as neg brotle syndroms.

Hydrochicosticatio tablets are indicated in the management of ingenturation either as the sole therapeutic agent or to enhance the effectiveness of other satinguartessive drugs in the more several terms of ingenturation.

Note in registron of districts during normal programs; is improportial and oppose mother and faites to unecessary bound. Districts do not posent development of bounds of programs and there is no satisfacting vertices that they are sent at in the bouleand of bounds.

Element during programs may order that programs pointings of casts, just as they are in the bouleand of bounds.

Element during programs may order that programs and the second programs of the pro

CONTRAINDICATIONS

Hypersensitivity to this product or to other sulforgenide-derived drags.

Use with oscition in severo ronal disease. In potients with ronal disease, this cides may precipitals azotomia. Cumulative effects of the drug may develop in patients with impaired small function.

This tribus should be used with exaction in patients with impaired hapatic function or progressive liter of bease, since minerally rations of fluid and electrify to be browning procipitate hapatic corns.
This tribus may said to or potentials the action of other antity gentancies sings.

Specifielty reactions may occur in policints with an without a history of allogy or branchial cathera.

The possibility of assemblation or activation of system bilingue or phemodera on his bean reported.

Lithium generally chould not be given with duratics (see PREGAUTIONS, Drug interactions).

PRECAUTIONS

Ap plants receiving the selectharmay should be observed for weldence of the life or electrolysis indexisnous names), in ponetiments, it speech to remission and particularly important when they plant is verified; concented; or country in the control of the contr tack years a, and general manual arms of the prolonged the rapy.

sware diministric power, or star printingsof berggs, interference with adoption or all schedule interference and size contribute to high startine. High startine may cause continue an application in the start in the bode of block of light tip is of, interested work our initiality. High startine may be avoided on basel by problem language distances or protection supplements such as foot with high protection content.

Afficially any chief to define it is generally mit at adult as adult case, the many specific hardman count and are content of the starting of the start or protections of countributes of the starting of

in districts patients decage adjustments of insulin or oral hypoglycenic agents may be required. Hypoglycenic may occur with this side diseases. Thus latent districts mellitus may become manifest during this side than sp.

The entity performing afforts of the drug may be enhanced in the post-sympathectomy patient.

If progressive renal impairment becomes evident, consider withholding or discontinuing dissettic therapy.

This ticks have been a hiven to increase the union precedent of registering the may settle that the promption of the process. This ticks may defend the promption of the process of the pr

increases in cholesterol and triglyceride levels may be associated with this title diuratic therapy

Laberstory Tests

rmination of surum electrolytes to defect possible electrolyte imbalance should be done at appropriate intervals.

Drug Interactions

When give a concurrently the following drugs may interset with this side disreties.

Ababal haththrates, or misofice Potentiation of orthostatic hypotension may accur

Antibilitation drage- (seal agents and results)
Desage adjustment of the antibilitate to drug may be required.

Other antiferendental to division

Acid it we affact or patentistion. Chole dynamine and od artipol mains

Absorption of hydrochia tot hiscide is impaised in the presence of an innic each ange resim. Single classe of either choiset pramitie or colectioni resins bind the hydrochiann bisside and reduce its absorption from the gestroin@dinal tract bij up to 95 and 43 percent, respectively.

Configuration ACOV Infuncified electrolyte displation, particularly hypoitals mia.

Propost aminos (e.g., respirepirina)

Prosible decreased response to pressor amines but not sufficient to preclude their use

Shalatal amouto colorants, numberoshalating (ag., labaroantro) Possible increased responsivements to the muscle relaterat.

Uhlan

Generally cheuld not be given with discrete. Olaratic against reduce the renal clearance of lithium and add a high dok of lithium booking. Faster to the parkage insurt for lithium preparations before use of such proparations with hydrock brothstade.

Man-absorbitation - Antanament by Grago in some patients, the administration of a num-steed and information, again can reduce the disease, not antihoperture to check or thou, potentium-apoints and habits districts. Therefore, which information between character and number of check or as used condentiately, the potent is been the observed deceip to determine if the between the other of the district. In obtained.

Drug/LaboratoryText Interactions

Tristation should be discentineed below conjung out tests for parathyroid function (see PRECAUTIONS, Governi). Corolinogoeses, Martage este, Impelment of Fertitity

The year facility of stake in mice and ratio conducted under the expises of the Nothmal Toxicology Program (MTP) processed no evidence of a certificaperic planted of high cohortheartists is formed in the just does of up to approximately 900 mg/kg/s/s in mode and transfer not just does of up to approximately 900 mg/kg/s/s in mode and transfer not just does of approximately 900 mg/kg/s/s. That PTP, hence not proposed evidence for the protect event possible in media and transfer not just does not does not be approximately of the protection of the pr

Hydrochitrothisatished no adverse effects on the fertility of mise and rats of either see in studies wherein these species were exposed, via tifeir diet, to doses of up is 100 and 4 mg/kg, respectively, prior to concept on and throughout gestation.

Braboush Effech - Programmy Cabony S

ADVERSE REACTIONS

The following act reactions have been reported and, within each estegory, are listed in the order of decreasing sewarity.

Bedy as a whole

Cardimonadas

Heorizansian including orthodoxic Heorizansian (may be approvated by sixphot, barbit analos, narrottes ar and hypertansive drugs)

Parcrealitis, joundice (introhopatic cholestatic joundice), diarrhae, vomiting cialedentile, cramping, constipution, gastric imbation, neuroes, anereda

Temahingio

A plantic snemia, agranu incritorio, laukopania, hamni eticanamia, thrombocetopania.

- pervious my Anni highest resoltions, secretizing anglife (vacculitis and culcinaries vacculitis), respiratory dictions lecturing presented in pulmonary admin, proteomething, train, criticals, notin, purputs.

Metabolic

Bectrulyts imbalance (see PRECAUTIONS), hyperglycomia, glyccouria, hyperunicomia

Musele spaare Hernous Syntam/Psychiatric

Vertigo, pasesthesias, dizziness, heatache, sestiessness

Rand failure, rand dysturction, intentitial naph titls (see WARHINGS). Environs multiforma including Stavens - Johnson syndroma, actolistive darmstitis including tode opidermal secreticis, alequeta

Translant transdiction, earthoosis

tregerital

then were adverse searchisms are moderate or severe, this side diseage should be reduced or the say with drawn

OVERDOS AGE

oversoon was:
The most common signs and symptoms observed as a those caused by electrolyte deplatin i hypotalamia, hypothicsenia, hypothicsen

The snal LD $_{\rm SS}$ of hydrochlosothic side is greater than 10 g/kg in the messe and sat.

DOSAGE AND ADMINISTRATION

Therapy should be individualized according to patient wasponce. Use the one liest discage necessary to achieve the required response.

For Blanca

The usual adult disago is 25 to 100 mg daily as a single or divided dose, Many patients with extern respond to informittent therapy. Lo, administration or administration days or or three-for five sole each week. With an informittent orbindule, accessive response and the reduling undertable electrolyte individual area less likely to occur.

The seal in that draw in adults is 25 mg daily given as a single dose. The dose may be increased to 50 mg daily, given on a cingle or two divided doses. Dose above 50 mg are intern associated with manifect reductions in series in potassism (see also PRESAUTIONES). Politicals associally do not require doses in excess of 50 mg of hydroch inrothleaded ally when used concomitantly with other antitry particular.

Infants and Children

For Shrook and For Control of Hyperboaden

The usual pudiatric diceage is 0.5 to 1 mg pur power()! to 2 mg/toj pur day in single or here divided diseas, not to exceed \$7.5 mg par day in single on her didease or only or 100 mg/pid (day) in didease 3 to 12 bits or d'app. in Moreire less than 6 months of app, dicease up to 1.5 mg/per power() single power() par mg/to who didease mg/to power() client for applications of mg/to power(). BOW SUPPLIED

Hydrochibrochibrochis Tableto USP, 25 mg ara light pink colored, round a fapad, flat faced baseled edge a socialed hibbas, debased with "D' and "D" on one olde appraisad by ecoloring and pin nor the other side. Enterjoine" of "Distriction" DIS C4458-SSI-10

PRARMACIST: Dispense in a well-closed container as defined in the USP. Use child-sesistant closure (as sequired). Store at 20" to 25"C (68" to 77" F); excussions permitted to 15" to 50°C (50" to 86"F) [see USP Controlled Room Temperature]

> Hyderabad-500 072, India Parkaged by International Labe, Inc. St. Potentium, R. 33710

Sax 13/00 LINCOS

Distributed by: International Labs, Inc.

Revised: 02/2010